Rituximab based treatment in pediatric Epsstain Bar Virus associated lymphocyte proliferative diseases after aplastic anemia with haplo-identical transplantation:a prospective single centre study
10.3760/cma.j.cn121090-20231229-00345
- VernacularTitle:利妥昔单抗为基础治疗儿童再生障碍性贫血单倍体移植后EB病毒相关淋巴细胞增殖性疾病的前瞻性单中心临床研究
- Author:
Feng ZHANG
1
;
Guanhua HU
;
Pan SUO
;
Zhengli XU
;
Lu BAI
;
Huifang WANG
;
Shanyamei HUANG
;
Lanping XU
;
Yingjun CHANG
;
Xiaohui ZHANG
;
Xiaojun HUANG
;
Yifei CHENG
Author Information
1. 北京大学人民医院，北京大学血液病研究所，国家血液系统疾病临床医学研究中心，造血干细胞移植北京市重点实验室，北京 100044
- From:
Chinese Journal of Hematology
2024;45(7):678-682
- CountryChina
- Language:Chinese
-
Abstract:
Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorders (PTLD) are one of the most severe complications after hematopoietic stem cell transplantation (HSCT). This study includes 31 cases of aplastic anemia (AA) patients who developed PTLD after haploidentical transplantation, summarizing their clinical characteristics and categorizing them into either rituximab monotherapy group or combination therapy group based on whether their condition improved by 1 log after a single dose of rituximab. The incidence of PTLD after HSCT in children with AA was 10.16%, and the incidence of PTLD in patients with age >10 years was significantly increased ( χ2=11.336, P=0.010). Of the 31 patients, 27 were clinically diagnosed and 4 were pathologically confirmed. Finally, 15 patients were classified into the rituximab treatment group and 15 patients into the combination treatment groups. Finally three patients died, and the 2-year overall survival rate was (89.7±5.6) %. Standard pre-treatment protocols and EBV reactivation are risk factors affecting the prognosis of PTLD. There was no statistically significant difference in the impact of the two treatment schemes on prognosis.
